Analysis of Circulating Tumor Markers in Blood - ALCINA 5 (NCT07060950) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
France620 participantsStarted 2025-10
Plain-language summary
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
✓. 18 years old or higher ?
✓. Patient who has provided informed, written, and explicit consent,
✓. Patient affiliated with a French Social Protection System.
✓. Tumor considered as accessible by biopsy,
✓. Normal hemostasis assessment (PT, APTT, platelets),
✓. No anticoagulant or antiaggregant treatment for the biopsy.
Exclusion criteria
✕. Pregnant woman and/or breast-feeding,
✕. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
✕. Private persons of freedom or under guardianship,
What they're measuring
1
All Cohorts : Study of the feasibility of detecting and/or analysing blood or tissue tumour biomarkers.
Timeframe: 10 years
Trial details
NCT IDNCT07060950
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle